Sitar Edward J 4
4 · INNOVATE BIOPHARMACEUTICALS, INC. · Filed May 4, 2020
Insider Transaction Report
Form 4
Sitar Edward J
Chief Financial Officer
Transactions
- Purchase
Series A Convertible Preferred Warrant
2020-05-04+678→ 67,800 totalFrom: 2020-05-04Exp: 2025-05-04→ Common stock (67,800 underlying) - Purchase
Series A Convertible Preferred Stock
2020-05-04+678→ 67,800 totalFrom: 2020-05-04→ Common stock (67,800 underlying)
Footnotes (2)
- [F1]The purchase price of the Series A Convertible Preferred Stock was $58.94 per share. The Series A Preferred Stock is convertible into Common Stock upon stockholder approval on a 1-for-100 basis, with no expiration date.
- [F2]The purchase price of the warrant was included with the purchase price of the Series A Convertible Preferred Stock. The Series A Preferred Warrant is convertible into Series A Preferred Stock on a 1-for-1 basis.